Key regions: Japan, India, Italy, Brazil, South Korea
The Anti-Hypertensive Drugs market in Burkina Faso has been experiencing steady growth in recent years.
Customer preferences: Burkina Faso has a high prevalence of hypertension, with an estimated 30% of the population affected. This has led to an increase in demand for anti-hypertensive drugs. Additionally, the country has a low doctor-to-patient ratio, which means that many patients rely on self-medication or advice from pharmacists. Therefore, affordability and accessibility are important factors for customers when choosing anti-hypertensive drugs.
Trends in the market: The market for anti-hypertensive drugs in Burkina Faso is dominated by generic drugs, which are more affordable than branded drugs. However, there is a growing demand for branded drugs, particularly those from multinational pharmaceutical companies. This is due to the perception that branded drugs are of higher quality and more effective. Another trend in the market is the increasing availability of combination drugs, which offer convenience for patients by combining multiple drugs into a single pill.
Local special circumstances: One of the unique characteristics of the Burkinabe market is the high prevalence of traditional medicine. Many patients prefer to use traditional remedies, such as herbal teas, to manage their hypertension. This has led to a growing interest in integrating traditional medicine with modern medicine. Additionally, the country has a weak regulatory environment, which makes it easier for counterfeit drugs to enter the market.
Underlying macroeconomic factors: Burkina Faso is one of the poorest countries in the world, with a low GDP per capita. This means that affordability is a major concern for customers when purchasing anti-hypertensive drugs. Additionally, the country has a weak healthcare system, which limits access to healthcare services for many people. This has led to a reliance on self-medication and advice from pharmacists. However, the government has made efforts to improve access to healthcare services and increase the availability of essential medicines, including anti-hypertensive drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
